{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:30:28Z","timestamp":1740123028817,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T00:00:00Z","timestamp":1630972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biotechnol Lett"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10529-021-03174-2","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T04:02:49Z","timestamp":1630987369000},"page":"2137-2147","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB\/c mice against influenza A\/PR8\/H1N1 virus challenge"],"prefix":"10.1007","volume":"43","author":[{"given":"Mehrnaz","family":"Forqani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Masoud","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behrokh","family":"Farahmand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadiseh","family":"Shokouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Torabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9386-0354","authenticated-orcid":false,"given":"Fatemeh","family":"Fotouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,7]]},"reference":[{"key":"3174_CR1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.3389\/fimmu.2013.00114","volume":"4","author":"S Awate","year":"2013","unstructured":"Awate S, Babiuk L, Mutwiri G (2013) Mechanisms of action of adjuvants. Front Immunol 4:114","journal-title":"Front Immunol"},{"key":"3174_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fimmu.2016.00641","volume":"7","author":"C Bernelin-Cottet","year":"2016","unstructured":"Bernelin-Cottet C, Deloizy C, Stanek O, Barc C, Bouguyon E, Urien C, Da Costa B (2016) A universal influenza vaccine can lead to disease exacerbation or viral control depending on delivery strategies. Front Immunol 7:641","journal-title":"Front Immunol"},{"key":"3174_CR3","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1016\/S0264-410X(98)00140-6","volume":"16","author":"ED Bernstein","year":"1998","unstructured":"Bernstein ED, Gardner EM, Abrutyn E, Gross P, Murasko DM (1998) Cytokine production after influenza vaccination in a healthy elderly population. Vaccine 16:1722\u20131731","journal-title":"Vaccine"},{"key":"3174_CR4","first-page":"4168","volume":"181","author":"D Carragher","year":"2008","unstructured":"Carragher D, Kaminski D, Moquin A, Hartson L, Randall T (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol Res 181:4168\u20134176","journal-title":"J Immunol Res"},{"key":"3174_CR5","doi-asserted-by":"publisher","first-page":"6597","DOI":"10.1016\/j.vaccine.2006.05.082","volume":"24","author":"M De Filette","year":"2006","unstructured":"De Filette M, Fiers W, Martens W, Birkett A, Ramne A, L\u00f6wenadler B, Saelens X (2006a) Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597\u20136601","journal-title":"Vaccine"},{"key":"3174_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.vaccine.2005.08.061","volume":"24","author":"M De Filette","year":"2006","unstructured":"De Filette M, Ramne A, Birkett A, Lycke N, L\u00f6wenadler B, Jou W, Fiers W (2006b) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:544\u2013551","journal-title":"Vaccine"},{"key":"3174_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11262-010-0547-7","volume":"42","author":"S Ebrahimi","year":"2011","unstructured":"Ebrahimi S, Tebianian M (2011) Influenza A viruses: why focusing on M2e-based universal vaccines. Virus Genes 42:1\u20138","journal-title":"Virus Genes"},{"key":"3174_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature06939","volume":"453","author":"S Eisenbarth","year":"2008","unstructured":"Eisenbarth S, Colegio O, O\u2019Connor W, Sutterwala F, Flavell RA (2008) Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453:1122\u20131126","journal-title":"Nature"},{"key":"3174_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11262-018-1609-5","volume":"55","author":"B Farahmand","year":"2019","unstructured":"Farahmand B, Taheri N, Shokouhi H, Soleimanjahi H, Fotouhi F (2019) Chimeric protein consisting of 3M2e and HSP as a universal influenza vaccine candidate: from in silico analysis to preliminary evaluation. Virus Genes 55:22\u201332","journal-title":"Virus Genes"},{"key":"3174_CR10","doi-asserted-by":"publisher","first-page":"6280","DOI":"10.1016\/j.vaccine.2009.07.007","volume":"27","author":"W Fiers","year":"2009","unstructured":"Fiers W, De Filette M, El Bakkouri K, Schepens B, Roose K, Schotsaert M, Saelens X (2009) M2e-based universal influenza A vaccine. Vaccine 27:6280\u20136283","journal-title":"Vaccine"},{"key":"3174_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.antiviral.2013.01.010","volume":"98","author":"X Gao","year":"2013","unstructured":"Gao X, Wang W, Zhang S, Duan Y, Xing L, Wang X (2013) Enhanced influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge. Antivir Res 98:4\u201311","journal-title":"Antivir Res"},{"key":"3174_CR12","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00705-010-0756-3","volume":"155","author":"L Guo","year":"2010","unstructured":"Guo L, Zheng M, Ding Y, Yang Z, Wang H, Chen Z (2010) Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol 155:1765\u20131775","journal-title":"Arch Virol"},{"key":"3174_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.vaccine.2007.10.062","volume":"26","author":"J Huleatt","year":"2008","unstructured":"Huleatt J, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Umlauf S (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201\u2013214","journal-title":"Vaccine"},{"key":"3174_CR14","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1126\/science.1089926","volume":"304","author":"M Jordan","year":"2004","unstructured":"Jordan M, Mills D, Kappler J, Marrack P, Cambier J (2004) Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 304:1808\u20131810","journal-title":"Science"},{"key":"3174_CR15","doi-asserted-by":"crossref","unstructured":"Kaiser J (2006) A one-size-fits-all flu vaccine. Sience|AAAS 380\u2013382","DOI":"10.1126\/science.312.5772.380"},{"key":"3174_CR16","first-page":"3755","volume":"181","author":"M Kool","year":"2008","unstructured":"Kool M, P\u00e9trilli V, De Smedt T, Rolaz A, Hammad H, Van Nimwegen M, Tschopp J (2008) Cutting edge: Alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol Res 181:3755\u20133759","journal-title":"J Immunol Res"},{"key":"3174_CR17","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/0092-8674(85)90211-9","volume":"40","author":"R Lamb","year":"1985","unstructured":"Lamb R, Zebedee S, Richardson C (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627\u2013633","journal-title":"Cell"},{"key":"3174_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7774\/cevr.2014.3.1.12","volume":"3","author":"Y Lee","year":"2014","unstructured":"Lee Y, Kim K, Ko E, Lee Y, Kim M, Kwon Y, Kang S (2014) New vaccines against influenza virus. Clin Exp Vaccine Res 3:12\u201328","journal-title":"Clin Exp Vaccine Res"},{"key":"3174_CR19","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.1128\/JVI.00120-13","volume":"87","author":"Z Li","year":"2013","unstructured":"Li Z, Gabbard J, Mooney A, Gao X, Chen Z, Place R, He B (2013) Single-dose vaccination of a recombinant parainfluenza virus 5 expressing NP from H5N1 virus provides broad immunity against influenza A viruses. J Virol 87:5985\u20135993","journal-title":"J Virol"},{"key":"3174_CR20","doi-asserted-by":"publisher","first-page":"e61775","DOI":"10.1371\/journal.pone.0061775","volume":"8","author":"M MacLeod","year":"2013","unstructured":"MacLeod M, David A, Jin N, Noges L, Wang J, Kappler J, Marrack P (2013) Influenza nucleoprotein delivered with aluminium salts protects mice from an influenza A virus that expresses an altered nucleoprotein sequence. PLoS ONE 8:e61775","journal-title":"PLoS ONE"},{"key":"3174_CR21","first-page":"25","volume":"15","author":"E Mardanova","year":"2015","unstructured":"Mardanova E, Kotlyarov R, Kuprianov V, Stepanova L, Tsybalova L, Lomonossoff G, Ravin N (2015) High immunogenicity of plant-produced influenza based on the M2e peptide fused to flagellin. Biotechnol Lett 15:25","journal-title":"Biotechnol Lett"},{"key":"3174_CR22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","volume":"22","author":"M Mbow","year":"2010","unstructured":"Mbow M, De Gregorio E, Valiante N, Rappuoli R (2010) New adjuvants for human vaccines. Curr Opin Immunol 22:411\u2013416","journal-title":"Curr Opin Immunol"},{"key":"3174_CR23","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1016\/j.vaccine.2004.07.050","volume":"23","author":"G Morefield","year":"2005","unstructured":"Morefield G, Sokolovska A, Jiang D, HogenEsch H, Robinson J, Hem S (2005) Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 23:1588\u20131595","journal-title":"Vaccine"},{"key":"3174_CR24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev-med-120611-145115","volume":"64","author":"N Pica","year":"2013","unstructured":"Pica N, Palese P (2013) Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med 64:189\u2013202","journal-title":"Annu Rev Med"},{"key":"3174_CR25","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1016\/j.vaccine.2007.03.006","volume":"25","author":"S Rafati","year":"2007","unstructured":"Rafati S, Gholami E, Hassani N, Ghaemimanesh F, Taslimi Y, Taheri T, Soong L (2007) Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients. Vaccine 25:4159\u20134169","journal-title":"Vaccine"},{"key":"3174_CR26","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.vaccine.2016.01.028","volume":"34","author":"C Rappazzo","year":"2016","unstructured":"Rappazzo C, Watkins H, Guarino C, Chau A, Lopez JL, DeLisa M, Putnam D (2016) Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB\/c mice. Vaccine 34:1252\u20131258","journal-title":"Vaccine"},{"key":"3174_CR27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","volume":"30","author":"S Reed","year":"2009","unstructured":"Reed S, Bertholet S, Coler R, Friede M (2009) New horizons in adjuvants for vaccine development. Trends Immunol 30:23\u201332","journal-title":"Trends Immunol"},{"key":"3174_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s10529-020-02822-3","author":"M Saleh","year":"2020","unstructured":"Saleh M, Nowroozi J, Farahmand B, Fotouhi F (2020) An approach to the influenza chimeric subunit vaccine (3M2e-HA2-NP) provides efficient protection against lethal virus challenge. Biotechnol Lett. https:\/\/doi.org\/10.1007\/s10529-020-02822-3","journal-title":"Biotechnol Lett"},{"key":"3174_CR29","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.virusres.2018.05.003","volume":"251","author":"H Shokouhi","year":"2018","unstructured":"Shokouhi H, Farahmand B, Ghaemi A, Mazaheri V, Fotouhi F (2018) Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge. Virus Res 251:40\u201346","journal-title":"Virus Res"},{"key":"3174_CR30","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/0264-410X(95)92777-Y","volume":"13","author":"VA Slepushkin","year":"1995","unstructured":"Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13:1399\u20131402","journal-title":"Vaccine"},{"key":"3174_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3201\/eid1201.051237","volume":"12","author":"P Thomas","year":"2006","unstructured":"Thomas P, Keating R, Hulse-Post D, Doherty P (2006) Cell-mediated protection in influenza infection. Emerg Infect Dis 12:48","journal-title":"Emerg Infect Dis"},{"key":"3174_CR32","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3201\/eid1303.061125","volume":"13","author":"S Tompkins","year":"2007","unstructured":"Tompkins S, Zhao Z, Lo C, Misplon J, Liu T, Epstein S (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13:426","journal-title":"Emerg Infect Dis"},{"key":"3174_CR33","doi-asserted-by":"publisher","first-page":"e52488","DOI":"10.1371\/journal.pone.0052488","volume":"7","author":"W Wang","year":"2012","unstructured":"Wang W, Huang B, Jiang T, Wang X, Qi X, Gao Y, Ruan L (2012) Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP\u2013M2e fusion protein expressed in E. coli. PLoS ONE 7:e52488","journal-title":"PLoS ONE"},{"key":"3174_CR34","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1016\/j.vaccine.2020.07.015","volume":"38","author":"J Wei","year":"2020","unstructured":"Wei J, Li Z, Yang Y, Ma X, An W, Ma G, Zhang S (2020) A biomimetic VLP influenza vaccine with interior NP\/exterior M2e antigens constructed through a temperature shift-based encapsulation strategy. Vaccine 38:5987\u20135996","journal-title":"Vaccine"},{"key":"3174_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2014.08.008","volume":"111","author":"P Yang","year":"2014","unstructured":"Yang P, Wang W, Gu H, Li Z, Zhang K, Wang Z, Wang X (2014) Protection against influenza H7N9 virus challenge with a recombinant NP\u2013M1\u2013HSP60 protein vaccine construct in BALB\/c mice. Antivir Res 111:1\u20137","journal-title":"Antivir Res"},{"key":"3174_CR36","first-page":"7","volume":"7","author":"Z Yousefi-Najafabadi","year":"2013","unstructured":"Yousefi-Najafabadi Z, Behzadian F, Fotouhi-Chahooki F, Farahmand B (2013) Prokaryotic expression of influenza A virus nucleoprotein fused to mycobacterial heat shock protein70. Iran J Virol 7:7\u201314","journal-title":"Iran J Virol"},{"key":"3174_CR38","doi-asserted-by":"publisher","first-page":"7233","DOI":"10.1016\/j.vaccine.2010.08.049","volume":"28","author":"G Zhao","year":"2010","unstructured":"Zhao G et al (2010a) Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 28:7233\u20137240","journal-title":"Vaccine"},{"key":"3174_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1743-422X-7-1","volume":"7","author":"G Zhao","year":"2010","unstructured":"Zhao G, Lin Y, Du L, Guan J, Sun S, Sui H, Zheng B (2010b) An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J 7:1\u20138","journal-title":"Virol J"},{"key":"3174_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s15010-013-0546-4","volume":"42","author":"M Zheng","year":"2014","unstructured":"Zheng M, Luo J, Chen Z (2014) Development of universal influenza vaccines based on influenza virus M and NP genes. Infection 42:251\u2013262","journal-title":"Infection"}],"container-title":["Biotechnology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-021-03174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10529-021-03174-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10529-021-03174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T22:32:25Z","timestamp":1634077945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10529-021-03174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,7]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3174"],"URL":"https:\/\/doi.org\/10.1007\/s10529-021-03174-2","relation":{},"ISSN":["0141-5492","1573-6776"],"issn-type":[{"type":"print","value":"0141-5492"},{"type":"electronic","value":"1573-6776"}],"subject":[],"published":{"date-parts":[[2021,9,7]]},"assertion":[{"value":"7 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the animal experiments were approved and performed based on the guidelines of the Ethical Committee of the Pasteur Institute of Iran, Tehran, Iran (IR.PII.REC.1395.82).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}